Jason Crosson, MD
Ophthalmology · Apo, AENPI 1558536169
Payments from drug & device makers
Across 36 payments — averaging $1264.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$23K
- Regeneron$11K
- AstraZeneca$9K
- US Retina LLC$1K
- Spark Therapeutics, Inc.$380
- Alcon$342
- plus $289 from 3 others
What the payments were for
- Food & beverage$1,01143%
- Ownership interest$1,36157%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 10 | $22,988 |
| Regeneron | 3 | $11,470 |
| AstraZeneca | 2 | $8,690 |
| US Retina LLC | 5 | $1,361 |
| Spark Therapeutics, Inc. | 7 | $380 |
| Alcon | 6 | $342 |
| Novartis | 1 | $122 |
| Janssen Global Services, LLC | 1 | $114 |
| Apellis Pharmaceuticals, Inc. | 1 | $53 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few ophthalmology providers in AEto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 162 | $8,709 |
| Bromfenac Sodium | 67 | $7,770 |
| Difluprednate | 61 | $5,188 |
| Ketorolac Tromethamine | 149 | $3,906 |
| Brimonidine Tartrate | 55 | $2,606 |
| Atropine Sulfate | 46 | $1,818 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 111 | $1,739 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 106 | $1,388 |
| Valganciclovir Hcl | 11 | $684 |
| Timolol Maleate | 49 | $538 |
| Latanoprost | 42 | $531 |
| Ofloxacin | 11 | $213 |
| ErythromycinErythromycin Base | 16 | $173 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Apo
- Paula YoungApo$2K
- Christiaan KroesenApo$1K
- Euisun ChungApo$706
- Andrew PanApo$302
- Jane WhitneyApo$161
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.